Skip to main content
Log in

Clinical pharmacokinetics of alcuronium chloride in man

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetic behaviour of alcuronium is described for nineteen patients undergoing anaesthesia for elective surgery. Eleven patients received a single bolus intravenous dose of 0.25 mg/kg, while 8 patients required additional doses of 0.125 mg/kg. A two-compartment open model was found to describe adequately both the single dose and multiple dose data for the majority of patients. No significant differences were found in the model-independent pharmacokinetic parameters between the single and multiple dose studies. Mean values for the pooled data for the half-life (t1/2β), apparent volume of distribution (Vdβ), volume of distribution at steady-state (Vdss), volume of the central compartment (Vc) and plasma clearance (Clp) were 198.75 min, 24.261, 20.891, 8.181 and 90.22 ml/min respectively. Evoked muscle twitch response was monitored in 17 of the patients to assess the degree of relaxant blockade. The bolus dose of alcuronium produced complete block in 9 patients and between 95 and 99% block in the remainder. The time of onset to maximum block ranged from 3 to 30 min with the concurrently measured plasma levels of alcuronium being 0.79 to 2.25 µg/ml. The time taken following bolus administration to 5% recovery (95% paralysis) was a mean of 42 min and the corresponding mean alcuronium plasma concentration was 0.78 µg/ml.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Agoston S, Vermeer GA, Kersten UW, Meijer DKF (1973) The fate of pancuronium bromide in man. Acta Anaesth Scand 17: 267–275

    Google Scholar 

  • Ali HH, Savarese JJ (1976) Monitoring of neuromuscular transmission. Anesthesiology 45: 216–249

    Google Scholar 

  • Barth L, Dannhorn R (1977) Prolonged neuromuscular activity of non-depolarising muscle relaxants, investigated by tetanic resistance. Anaesthesist 26: 116–124

    Google Scholar 

  • Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 2: 123–148

    Google Scholar 

  • Buzello W (1975) Der Stoffwechsel von Pancuronium beim Menschen. Anaesthesist 24: 13–18

    Google Scholar 

  • Buzello W, Agoston S (1978) Comparative clinical pharmacokinetics of d-tubocurarine, gallamine, alcuronium and pancuronium. Anaesthesist 27: 313–318

    Google Scholar 

  • Dwyer BE, Gunner BW, Walker WD (1967) Diallyl-nortoxiferine (“Alloferin”). A clinical appraisal. Aust N Z J Surg 37: 54–57

    Google Scholar 

  • Goldstein A (1964) Biostatistics: an introductory text. Macmillan, New York, p 51

    Google Scholar 

  • Hügin W, Kissling P (1961) Vorläufige Mitteilungen über ein neues kurzwirkendes Relaxans vom depolarisationshindernden Typus, das RO4-3816. Schweiz Med Wochenschr 91: 455–457

    Google Scholar 

  • Hügin W (1972) Muscle relaxants in surgery and the new compound ‘Alloferin’ Roche. In: Alloferin, medium-long-acting muscle relaxant of the non-depolarising type. F. Hoffman — La Roche and Co. Ltd. Basle, Switzerland

    Google Scholar 

  • Katz RL, Katz GJ (1975) In: Katz RL (ed) Muscle relaxants. Excerpta Medica, Amsterdam pp 313–334

    Google Scholar 

  • Kersten UW, Meijer DKF, Agoston S (1973) Fluorimetric and chromotographic determination of pancuronium bromide and its metabolites in biological materials. Clin Chim Acta 44: 59–66

    Google Scholar 

  • Pederson PVL (1977) Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokin Biopharm 5: 513–531

    Google Scholar 

  • Raaflaub J, Frey P (1972) Zur Pharmacokinetik von diallyl-nor-toxiferin beim Menschen. Arzneim Forsch 22: 73–78

    Google Scholar 

  • Ramzan MI, Triggs EJ, Shanks CA (1980) Pharmacokinetic studies in man with gallamine triethiodide I. Single and Multiple Clinical doses. Eur J Clin Pharmacol 17: 135–143

    Google Scholar 

  • Shanks CA, Ramzan MI, Triggs EJ (1979) Studies in man with a constant-rate infusion of tubocurarine. Anaesth Intensive Care 7: 209–214

    Google Scholar 

  • Sheiner LB, Stanski DR (1979) Pharmacokinetics and dynamics of muscle relaxants. Anesthesiology 51: 103–105

    Google Scholar 

  • Somogyi AA, Shanks CA, Triggs EJ (1976) Clinical pharmacokinetics of pancuronium bromide. Eur J Clin Pharmacol 10: 367–372

    Google Scholar 

  • Thomas J, Climie CR, Mather LE (1969) Placental transfer of alcuronium. Br J Anaesth 41: 297–301

    Google Scholar 

  • Wagner JG (1976) Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4: 443–467

    Google Scholar 

  • Walts LF, Dillon JB (1968) Durations of action of d-tubocurarine and gallamine. Anesthesiology 29: 499–504

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walker, J., Shanks, C.A. & Triggs, E.J. Clinical pharmacokinetics of alcuronium chloride in man. Eur J Clin Pharmacol 17, 449–457 (1980). https://doi.org/10.1007/BF00570163

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00570163

Key words

Navigation